fda compounded tirzepatide warning 2024 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our March 10, 2025: Patients transitioning

Phentermine commonly causes insomnia and restlessness due to its stimulant properties, while tirzepatide commonly causes fatigue and low energy, particularly during dose escalation

A comprehensive approach addresses both the medication regimen and lifestyle factors

Formula C225H348N48O68

doi:10.4103/2230-8210.179997

While standard prescribing typically follows weekly injections, many patients and providers explore alternative dosing schedules like every-other-week administration to optimize long-term adherence and sustainability

During the first three quarters of 2025, Mounjaro sales nearly doubled (up 94%) from $8.010 billion to $15.558 billion, including $6.515 billion garnered in Q3 (more than double a year earlier)while Zepbound sales tripled from $3.018 billion to $9.281 billion, including $3.588 billion racked up in the July-September quarter, nearly triple (185%) Q3 2024